Clinical Trial Update: Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS) [Phase 3]

View source ↗

Summary

Phase 3 VENUS trial of rimonabant in Japanese obese patients with dyslipidemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Obesity

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Obesity | Phase 3 | Status: TERMINATED